Indication

Myasthenia gravis

Myasthenia gravis is a chronic autoimmune neuromuscular junction disorder characterized by fluctuating weakness and abnormal fatigability of voluntary skeletal muscles. Read more about Myasthenia gravis

34 drugs 23 manufacturers

Advertisement

Drugs that treat it

Common Myasthenia gravis therapies.

Showing 28–34 of 34 drugs

Filter & compare in the drug finder →Opens the drug finder with Myasthenia gravis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Myasthenia gravis.

Myasthenia gravis is a chronic autoimmune neuromuscular junction disorder characterized by fluctuating weakness and abnormal fatigability of voluntary skeletal muscles.

The condition is mediated primarily by pathogenic autoantibodies directed against acetylcholine receptors or related proteins at the postsynaptic motor endplate, disrupting normal neuromuscular transmission.

Clinically, symptoms typically worsen with repeated muscle use and improve with rest, frequently involving the ocular, bulbar, limb, or respiratory muscles.

Presentations range from localized ocular manifestations, such as ptosis and diplopia, to severe generalized weakness that can culminate in life-threatening respiratory failure known as a myasthenic crisis.

Personalize your experience

Follow Myasthenia gravis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it